Physician profile
Danielle Davaros
NPI 1356713648
$20,278.64
in general payments reported to CMS, 2019-2025
28 companies · $4,982 in 2025
The $4,982 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,988 · 2022: $3,181 · 2023: $4,832 · 2024: $5,295 · 2025: $4,982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,459.06 |
| Education | $650.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,927.39 | 2021-2025 | |
| Leo Pharma INC. | $3,136.48 | 2021-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $1,422.89 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $1,303.51 | 2021-2025 | |
| Pfizer INC. | $1,276.08 | 2021-2025 | |
| Janssen Biotech, INC. | $1,157.60 | 2021-2025 | Tremfya, Simponi Aria |
| Dermavant Sciences, INC. | $1,082.08 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $991.12 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $972.47 | 2021-2025 | Dupixent, Libtayo |
| Incyte Corporation | $770.20 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $762.25 | 2021-2025 | Absorica Ld, Winlevi, Blu-U |
| Galderma Laboratories, L.P. | $751.57 | 2021-2025 | Nemluvio |
| Amgen INC. | $736.78 | 2022-2025 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $566.02 | 2022-2024 | Sotyktu |
| Organon LLC | $262.23 | 2025 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $238.10 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.00 | 2022-2024 | Spevigo |
| Ucb, INC. | $171.83 | 2024-2025 | Bimzelx |
| Almirall LLC | $124.86 | 2024 | Klisyri |
| Allergan, INC. | $105.49 | 2021-2022 | |
| Journey Medical Corporation | $82.13 | 2021-2023 | |
| Merz North America, INC. | $71.74 | 2021 | |
| Organogenesis INC. | $63.25 | 2023-2024 | Puraply |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.08 | 2021-2024 | Jublia, Arazlo, Cabtreo |
| Vyne Pharmaceuticals INC. | $29.04 | 2021 | |
| Dermira, INC. | $21.59 | 2021 | |
| Biofrontera INC. | $19.80 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Cipher Pharmaceuticals US LLC | $16.06 | 2025 | Natroba, Spinosad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Davaros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.